Sarcopenia in Critical Care Settings Following Major Surgical Procedures

Sarcopenia in Intensive Care Unit (ICU) settings represents a major clinical challenge that enhances patient's morbidity, mortality, and healthcare costs. Although it significantly impacts patient outcomes, conventional specialist care frequently focuses on isolated organ systems rather than addressing the comprehensive challenges of frailty and progressive muscle loss. Many elderly patients present with pre-existing sarcopenia upon hospital admission, a condition primarily driven by poor nutritional habits and loss of appetite. Once in the ICU, this muscle wasting is drastically accelerated by an intricate web of interacting factors. Critical illness related catabolism, system inflammation, physical inactivity, and stress including pain, anxiety, sleep deprivation, and depression. Furthermore, essential ICU medications and interventions inadvertently exacerbate this decline. Narcotic analgesics like morphine like morphine and fentanyl, alongside numerous drugs possessing potent anticholinergic activity (such as specific antihistamines, muscle relaxants, tricycle antidepressants, antipsychotics, and anesthetics like scopolamine), severely inhibit gastrointestinal motility. This frequency results in ileus, impaired digestion, and compromised nutrient absorption, indirectly accelerating muscle breakdown. The cumulative toll of these physiological and pharmacological stressors is a rapid, progressive loss of muscle mass and strength. This decline severely complicates weaning from mechanical ventilation, extends hospital stays, and heightens the risk of long-term post-discharge disability. Ultimately, sarcopenia must be reframed as a central, interconnected component of critical illness rather than a secondary side effect. Effectively mitigating its impact demands a proactive, multidisciplinary approach centered on early risk identification, tailored nutritional optimization, aggressive early mobilization protocols, comprehensive psychological support, and vigilant, structured medication reviews to minimize adverse drug-induced metabolic effects.